ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy
Clara Aceves-Luquero(Hospital General Universitario de Albacete), Ricardo Sánchez‐Prieto(Consejo Superior de Investigaciones Científicas)
Cited by 47
Related Papers
Full Activation of PKB/Akt in Response to Insulin or Ionizing Radiation Is Mediated through ATM
|Journal of Biological Chemistry|2004|272
Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance
|Oncotarget|2015|49
ERK5/BMK1 Is a Novel Target of the Tumor Suppressor VHL: Implication in Clear Cell Renal Carcinoma
|Neoplasia|2013|40
Balance between MKK6 and MKK3 Mediates p38 MAPK Associated Resistance to Cisplatin in NSCLC
|PLoS ONE|2011|40
c‐Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin‐based therapy
|International Journal of Cancer|2007|37